NCT07138209

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 Randomized Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 228 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	QLS32015	QLS32015 will be administered subcutaneously.
DRUG	Pomalidomide	Pomalidomide will be administered orally.
DRUG	Selinexor	Selinexor will be administered orally.
DRUG	Dexamethasone	Dexamethasone will be administered orally

Timeline

• Start date: 2025-11-07
• Primary completion: 2027-12-01
• Completion: 2029-12-01
• First posted: 2025-08-22
• Last updated: 2026-02-27

Locations

1 site across 1 country: China